Clinical Trial Closeup

Edited by Emmett T. Cunningham Jr., MD, PhD

A Smaller, Faster Anti-VEGF Therapy

How brolucizumab may extend dosing out to 12 weeks.

Moving the Needle on Ocular Cancer

How AU-011 selectively targets melanoma without damaging nearby ocular tissue.

A Drop for DME and AMD

Are clinical investigators close to finding the Holy Grail for retinal disease?

Restoring Cell Function to Block VEGF

Integrin peptide therapy Luminate shows potential of extending DME treatment.

FA Insert Delivers At 12 Months

Top-line results through 12 months show sustained effect of three-year insert for noninfectious posterior uveitis.

Can a Gene Vector Work for Long Term?

Lentiviral vector expresses protein for up to four years in trial.

Can Brimonidine Reduce GA Progression?

Phase IIA trial shows potential of its neuroprotective properties for retinal disease.

Drugability of the Suprachoroidal Space

Phase II trial shows Clearside’s CLS-TA safe and effective in noninfectious uveitis.

APL-2’s Role in Blocking the GA Cascade

By inhibiting complement factor C3, Apellis bets it can prevent inflammation in advanced dry AMD

SPK-RPE65 Gene ‘Augmentation’

This biological agent targets mutations in genes that mediate visual transduction.

Video Vault

Managing Aphakia Without Capsular Support

Authors Clarissa S.M. Cheng, FRCOphth, Omar Kh Abu Al Ghanam, MBBSc, Felipe Dhawahir-Scala, FRCS (Ed), FRCOphth, LMS, demonstrate the various steps involved in implantation of the Artisan intraocular lens.